Efficacy and Safety of MG in the Patients With Alcoholic Fatty Liver Disease and Alcoholic Hepatitis

NCT02019056 ↗

Phase 2 Completed 90 enrolled PharmaKing

RandomizedParallel-groupDouble-blindTreatment

Summary

The Purpose of A Multicenter, Randomized, Double-blind, Placebo-controlled to Evaluate the Efficacy, Safety and Pharmacokinetics of MG in Patients With alcoholic Fatty Liver Disease and Alcoholic Hepatitis.

Timeline

Start: 2010-11
Primary completion: 2014-12
Completion: 2014-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	MG-1	Unknown	500 mg	—
Subject	MG-2	Unknown	1000 mg	Oral
Comparator	Metadoxine	Unknown	500 mg	Oral

Efficacy and Safety of MG in the Patients With Alcoholic Fatty Liver Disease and Alcoholic Hepatitis

Summary

Timeline

Drugs

Indications